Erasca
Develops pan-RAS and pan-KRAS therapies for RAS/MAPK-driven solid tumors.
$18.10
After-hours close+0.07 (+0.36%)
At close$18.04(−7.47%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.14 | — | — |
| Aug 2026 | −$0.11 | −$0.14 | −25.7% |
| Aug 2026 | −$0.11 | −$0.14 | −25.7% |
| May 2026 | −$0.12 | −$0.11 | +4.7% |
| Mar 2026 | −$0.11 | −$0.10 | +9.1% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Jul 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 11, 2026 | −$0.14 | — | — | — | — | — |
| Aug 12, 2026 | −$0.11 | −$0.14 | −25.7% | — | — | — |
| Aug 11, 2026 | −$0.11 | −$0.14 | −25.7% | — | — | — |
| May 11, 2026 | −$0.12 | −$0.11 | +4.7% | — | — | — |
| Mar 12, 2026 | −$0.11 | −$0.10 | +9.1% | — | — | — |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | ||||||
| Nov 12, 2025 | ||||||
| Aug 12, 2025 | ||||||
| May 13, 2025 | ||||||
| Mar 20, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Aug 12, 2024 | ||||||
| May 8, 2024 | ||||||
| Mar 27, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 15, 2023 | ||||||
| Mar 23, 2023 | ||||||
| Nov 9, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 12, 2022 | ||||||
| Mar 24, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 26, 2021 | ||||||
| Jul 16, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Sep 30, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||